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How the genomic landscape of a tumor shapes and
is shaped by anti-tumor immunity has not been sys-
tematically explored. Using large-scale genomic
data sets of solid tissue tumor biopsies, we quanti-
fied the cytolytic activity of the local immune infiltrate
and identified associated properties across 18 tumor
types. The number of predicted MHC Class I-associ-
ated neoantigens was correlated with cytolytic activ-
ity and was lower than expected in colorectal and
other tumors, suggesting immune-mediated elimina-
tion. We identified recurrently mutated genes that
showed positive association with cytolytic activity,
including beta-2-microglobulin (B2M), HLA-A, -B
and -C and Caspase 8 (CASP8), highlighting loss of
antigen presentation and blockade of extrinsic
apoptosis as key strategies of resistance to cytolytic
activity. Genetic amplifications were also associated
with high cytolytic activity, including immunosup-
pressive factors such as PDL1/2 and ALOX12B/
15B. Our genetic findings thus provide evidence for
immunoediting in tumors and uncover mechanisms
of tumor-intrinsic resistance to cytolytic activity.
INTRODUCTION
With the recent success of checkpoint blockade therapy (against
CTLA4 or PD1/PDL1) in inducing durable control of diverse
tumors (Hinrichs and Rosenberg, 2014; Sharma et al., 2011), it
has become critical to understand why some tumors are not
responsive or develop resistance to therapy. Predictors of
outcome have been identified in the context of spontaneous tu-
mor immunity (Bindea et al., 2013) and immunotherapy (Herbst
et al., 2014; Tumeh et al., 2014; Ji et al., 2012; Snyder et al.,
2014), but there remains a need for more extensive mechanistic
analyses of human tumor-immune interactions.48 Cell 160, 48–61, January 15, 2015 ª2015 Elsevier Inc.High-dimensional data sets—such as The Cancer Genome
Atlas (TCGA) that include genome-wide DNA sequencing, RNA
sequencing and copy number profiles—have made it possible
to dissect the factors driving malignancy with unprecedented
depth. Recent analyses of TCGA data sets have linked the
genomic landscape of tumors with tumor immunity, implicating
neoantigen load in driving T cell responses (Brown et al., 2014)
and identifying somatic mutations associated with immune infil-
trates (Rutledge et al., 2013). Here, we build on this work and use
the extensive TCGA data set to infer how tumors induce and
adapt to immune responses.
To identify and characterize the correlates of anti-tumor immu-
nity, we devised an RNA-basedmetric of immune cytolytic activ-
ity and calculated it for thousands of TCGA solid tumor samples.
By correlating this metric with genetic and non-genetic findings
from TCGA data, we set out to address several questions, in-
cluding: does cytolytic activity vary across tumor types? Does
the load of predicted neoantigens or viruses in a tumor explain
the cytolytic activity? Are particular recurrent mutations in tu-
mors associated with higher cytolytic activity, reflecting mecha-
nisms of tumor escape from cytolytic immune activities?
RESULTS
A Metric for Immune Cytolytic Activity Based on Gene
Expression in TCGA Tumors
To study immune effector activity in solid tumors, we focused on
cytotoxic T cells (CTL) and natural killer cells (NK) because of
their potent ability to kill tumor cells and numerous studies
showing that effector T cells at the tumor site predict favorable
outcome across many cancers (Page`s et al., 2005; Sato et al.,
2005; Schumacher et al., 2001). Using RNA-Seq data from thou-
sands of TCGA solid tumor biopsies, we devised a simple and
quantitative measure of immune cytolytic activity (‘‘CYT’’) based
on transcript levels of two key cytolytic effectors, granzyme A
(GZMA) and perforin (PRF1), which are dramatically upregulated
upon CD8+ T cell activation (Johnson et al., 2003) and during
productive clinical responses to anti-CTLA-4 and anti-PD-L1 im-
munotherapies (Ji et al., 2012; Herbst et al., 2014). Consistent
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Figure 1. Immune Cytolytic Activity Varies
across Tumor Types and Is Associated
with Suppressive Factors
(A) Cytolytic activity (CYT), defined as the log-
average (geometric mean) of GZMA and PRF1
expression in transcripts per million (TPM), is
shown for each of 18 TCGA tumor types and normal
tissues. Normal tissue samples include TCGA
controls and GTEx samples, excluding smokers for
lung tissues. Boxes in box plot represent inter-
quartile ranges and vertical lines represent 5th–95th
percentile ranges, with a notch for the median. p
values are unadjusted and calculated by Wilcoxon
rank-sum test (comparison to relevant normal), and
asterisks denote events significant at 10% FDR.
(B) The correlation of a gene with CYT across all
tumor types is shown (x axis) relative to its relative
expression in CTL/NK cells. Top right, genes ex-
pressed in CTL/NK cells that are associated with
CYT. Bottom right, non-CTL/NK genes associated
with CYT. Average Spearman correlation of
expression with CYT was calculated across 18
tumor types. y axis: for each gene, median
expression in NKs and CTLs divided by median
expression in non-hematopoietic cells using CAGE
data from Fantom5.
See also Data S1 and Table S1.with their coordinated roles,GZMA and PRF1were tightly co-ex-
pressed in TCGA samples (Data S1A and S1B) and showed CTL-
specific expression in panels of human cell types (Data S1C and
S1D), thus serving as highly specific markers in heterogeneous
tumor samples.Cell 160, 48–6We found that the levels of cytolytic ac-
tivitywere highest in kidney clear cell carci-
nomas and cervical cancers, lowest in gli-
oma and prostate cancers, and average
(albeit skewed to high levels) in melanoma
(Figure 1A; Table S1A and S1B). Most
normal tissues (from TCGA or the Geno-
type-Tissue Expression [GTEx] project
[GTEx Consortium, 2013]) showed defini-
tively lower (6 tissues) or equal (7 tissues)
cytolytic activity compared to their corre-
sponding tumors, but two showed defini-
tively higher activity (lung and colon). Of
note, CYT in colorectal tumors increased
considerably given high microsatellite
instability (MSI) (Data S1E) (Schwitalle
et al., 2008). The differences in cytolytic ac-
tivities across tumor types and compared
to normal tissues are likely to reflect a
combination of tissue- and tumor-specific
mechanisms that regulate local immunity.
Cytolytic Activity Is Associated with
Counter-Regulatory Immune
Responses and Improved Prognosis
To determine whether cytolytic activity is
associated with other immune cell types
and functions, we calculated the enrichment of 15 immune cell
type and function gene sets in the same samples (Table S1C;
expression data from Fantom5 project [FANTOM Consortium
et al., 2014]). While CYT showed moderate correlation with B
cells and weak correlation with macrophages, it showed strong1, January 15, 2015 ª2015 Elsevier Inc. 49
correlation with: (1) CTL markers, as expected; (2) plasmacytoid
dendritic cells; (3) counter-regulatory Tregs and known T cell co-
inhibitory receptors, as seen in chronic inflammatory conditions
(Data S1F) (Lund et al., 2008).We note that expression of the pre-
defined gene sets was similarly enriched in most tumor and
normal tissues, with some notable differences (Data S1G), and
not typically connected to tumor stage (Data S1H and S1I).
Finally, when we looked for CYT correlations with any transcript
(filtering out CTL and NK genes), we found that CYT was best
correlated with immunosuppressive factors (Spranger et al.,
2013), such as PDL2 (PDCD1LG2), IDO1/2, DOK3 (Lemay
et al., 2000), GMCSF receptor (CSF2RA, CSF2RB), and the
C1Q complex (Figure 1B). In addition, it was also associated
with interferon-stimulated chemokines (CXCL9, CLCL10, and
CXCL11) that attract T cells, as observed previously (Bindea
et al., 2013). We conclude that tumors can differ dramatically
in their infiltrate levels and composition, and that cytolytic activity
is associated with counter-regulatory activities that limit the im-
mune response.
When we used CYT and these other metrics to identify pre-
dictors of survival (controlling for tumor histology and stage),
we found that high CYT (and other T cell markers) is associated
with a modest but significant pan-cancer survival benefit (Data
S1J). While no individual immune cell type metrics were associ-
ated with poorer prognosis, higher expression of macrophage
markers relative to other markers was consistently linked with
poor prognosis, while higher expression of CYT or CTL markers
was correlated with improved prognosis (Data S1J).
Tumor Cytolytic Activity Is Associated with Oncogenic
Viruses in Some Tumors
Viruses account for a subset of malignancies and are also known
to activate high-affinity antigen-specific CTLs against non-self
viral antigens. Thus, we tested for correlation of cytolytic activity
levels with transcripts from oncogenic viruses—including Ep-
stein Barr virus (EBV), hepatitis B and C (HBV and HCV), human
papilloma virus (HPV), Kaposi sarcoma virus (KSV), and polyoma
viruses (Table S2A).
Consistent with previous analysis of TCGA data (Tang et al.,
2013), HPV infection was most abundant in cervical cancer
(91%), but also frequent in head and neck cancer (12%; with
more men than women, OR = 4.9; p = 8.5 3 104) and bladder
cancer (2%). We also observed occasional cases in colorectal,
kidney clear cell, glioma, lung squamous cell carcinoma, and
uterine cancer (Figure 2A). Only stomach cancer demonstrated
definitive instances of EBV infection (8%; Table S2A), which
was associated with high expression of specific EBV genes
EBER-1 and RPMS1 (Data S2A). Asian patients, known to
exhibit increased rates of stomach cancer (Jemal et al.,
2007), were not more likely than other stomach cancer patients
to harbor EBV (p = 0.63). Consistent with a role for viral in-
fection in the induction of CTLs, >2-fold increases in cytolytic
activity were observed in EBV+ versus EBV stomach cancers
and HPV+ versus HPV head and neck cancers, bladder can-
cers, uterine cancers and possibly cervical cancers (Figure 2B).
Strikingly, all the gene sets that were most tightly associated
with EBV infection in stomach cancer related to T cell activation
(Table S2B).50 Cell 160, 48–61, January 15, 2015 ª2015 Elsevier Inc.HBV and HCV were primarily observed in liver cancer (25%
and 5%, respectively), as expected, with occasional instances
of HBV infection in diverse tumor types. The extra-hepatic cases
did not exhibit hepatic gene expression signatures, suggesting
that these are not the result of metastases (Data S2B). We also
observed singleton cases of Kaposi sarcoma virus (lung squa-
mous cell carcinoma and stomach cancer), BK polyoma (bladder
cancer), and Merkel cell polyoma (ovarian cancer). While we did
observe type I interferon activation and B cell infiltration for
HCV+ liver cancer (Data S2C), these viruses did not show an
identifiable association with cytolytic activity.
To probe indirectly for the presence of viruses, we looked for
associations between CYT and two other correlates of viral infec-
tion, HLA genotype and APOBEC activity. While association with
HLAgenotypewas not observed for a single tumor type (although
there was a pan-cancer association with HLA-A31; Data S2D),
we did detect association with high APOBEC activity in tumors
with viral involvement (head and neck, cervical) and thosewithout
known viral involvement (breast, bladder) (Data S2E), suggesting
potential for unknown virus infections in some tumors.
Cytolytic Cells Are Likely to Be Targeting
Tumor Neoantigens
With recent studies from our group and others showing the pres-
ence of neoepitope-specific T cells in patients (Fritsch et al.,
2014), we tested for CYT association with the overall rate of mu-
tation and the rate of mutations predicted to yield a neoepitope
(i.e., an expressed peptide capable of binding each patient’s
imputed HLA alleles) (Data S3A and S3B, Table S3). On average,
50% of non-silent mutations yielded R1 predicted neoepitope
(with IC50 < 500 nM), and 39% of these impacted a substantially
expressed gene (median expression R10 TPM in the given
tissue type). Despite considerable inter-tumoral heterogeneity
(Table S4A), both metrics exhibited significant positive associa-
tion with CYT in multiple tumor types, most notably uterine can-
cer, breast cancer, stomach cancer, cervical cancer, and lung
adenocarcinoma (Figures 3A and 3B). Consistent with a smoking
etiology, lung adenocarcinomas from ever-smokers demon-
strated significantly higher CYT than those from never-smokers
(p = 0.003) (Data S3C). Melanomamutations exhibited a likely as-
sociation with CYT. Associations of mutations or neoepitopes
with CYT were matched by correlations for other T cell markers,
but less so with interferon-responsive genes (Data S3D and
S3E). These data are consistent with neoepitopes driving CYT
for many tumor types.
However, since the per-sample rate of neoepitope yielding
mutations closely tracks with the overall rate of mutation
(Spearman rho = 0.91; Data S3F), CYT may be driven by muta-
tion rate rather than neoepitopes. To test a role for neoepitopes,
we reasoned that T cell-mediated immune surveillance would
lead to elimination of immunogenic sub-clones expressing neo-
epitopes. To quantify neoepitope depletion, we determined how
the rate of predicted neoepitopes generated per non-silent point
mutation deviated from a null model based on the observed mu-
tation rate of silent point mutations. We found that colorectal
cancer and kidney clear cell cancer demonstrated dramatic
depletions of neoepitopes (Figure 3C; associated gene expres-
sion changes, Table S4B). Because neoepitope predictions are
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Figure 2. Viral Infection Is Tumor-Specific and Associated with Higher CYT in a Subset of Tumor Types
(A) Rates of viral infection, as defined by viral RNA-Seq read counts exceeding those observed in GTEx, for tumor types exhibiting at least one case. Isolated
cases of several other viruses were also observed.
(B) Distribution of CYT in tumor samples with (+) or without () viral infection. In tumor types affected by multiple viruses, ‘‘negative’’ samples include only those
negative for all viruses. Box plots as in Figure 1. p values are according to Wilcoxon rank-sum test.
See also Data S2 and Table S2.dependent on HLA genotypes, we reasoned that random shuf-
fling of HLA genotypes would abrogate the depletion signal (Fig-
ure S1). As expected, depletion was eliminated for colorectal
cancer and kidney clear cell cancer (and we note that the resid-
ual enrichment for other tumor types may reflect degeneracy of
peptide binding across HLA alleles). These findings are consis-
tent with a model in which immune surveillance activities cull
subclones expressing immunogenic antigens.
We conclude that neoepitopes are likely to be driving cytolytic
activity in a number of tumors, and that the resulting antigen-
specific CTLs can eliminate tumor clones harboring these
neoepitopes.
Ectopic Gene Expression, Endogenous Retroviruses,
and Necrosis Associated with CYT
Another potential source of tumor antigens is a unique set of
genes, known as cancer testis (CT) antigens, which are not ex-
pressed in healthy tissues, except germ cells, but are aberrantly
expressed in tumors and associated with antigen-specific re-sponses in patients harboring these tumors. Ectopic expression
is likely due to disturbances in genomic methylation and reacti-
vation of stem-like expression programs that may contribute to
tumorigenicity (Simpson et al., 2005). Using a set of 276 known
CT genes (Almeida et al., 2009), we used GTEx to identify a sub-
set of 60 that are transcriptionally silent in normal non-germline
tissues. Ectopic expression was observed for most tumor types,
especially melanoma, head and neck, lung, liver, stomach, and
ovarian cancer (Data S4A; Table S4A). In no tumor type was
there a clear positive association between the CYT and the count
of expressed CT antigens (Data S4B). We queried individual CT
antigens for correlation with CYT (Table S5A), and observed pos-
itive associations for CSAG2 in breast cancer (p = 1.2 3 1015),
head and neck cancer (p = 1.9 3 107), kidney clear cell cancer
(p = 9.93 105), and other tumor types. Associations for canon-
ical antigens, such as NY-ESO-1 (CTAG1), were less consistent.
We hypothesized that T cell surveillance would lead to CT anti-
gen silencing through chromosomal deletions, but compelling
evidence for this was not observed (Data S4C).Cell 160, 48–61, January 15, 2015 ª2015 Elsevier Inc. 51
A C
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Figure 3. Count of Predicted Antigenic Mutations per Sample Is Linked with Cytolytic Activity and Selectively Depleted in Certain Tumor
Types
(A) Local regression curves showing significant relationships betweenCYT and total mutation count in eight tumor types (p < 0.1, Spearman rank correlation), plus
melanoma (dotted line). Curves span the 5th to 95th percentile of the mutation count variable. Colors correspond to tumor type and are the same as appear in
Figure 1.
(B) Analogous to (A), but based on the count of point mutations predicted to yield an antigenic neo-epitope. Potential for antigenicity was defined based on gene
expression and potential to bind the corresponding patient’s imputed HLA with high affinity.
(C) For each tumor, the count of point mutations predicted to generate neo-epitopes was divided by the total count of non-silent point mutations to yield Bobs/
Nobs. This observed ratio was compared to an expected ratio, Bpred/Npred, estimated from the mutational spectra of the silent point mutations in the given sample
using an empirical model (Experimental Procedures). The ratio of the observed and predicted ratios represents the relative deviation of the neo-epitope rate from
expectation. p values reflect Wilcoxon rank-sum tests for deviation from 1.
Asterisks denote trends significant at 10% FDR for all panels. See also Figure S1, Data S3, Table S3, and Table S4.Endogenous retroviruses (ERVs) are another class of germ-
line-encoded elements that may be re-activated in tumors, and
we consideredwhether thesemight also contribute to anti-tumor
immunity. TLR7 or RAG knockouts in mice develop uncontrolled
ERV expression, ERV infectivity, and ERV insertion-driven tu-
mors (Young et al., 2012; Yu et al., 2012) yet little is known about
ERV-immune and ERV-cancer interactions in humans. Given re-
ports that these elements are transcriptionally and sometimes
even translationally active in humans (Boller et al., 1997; Schmitt
et al., 2013), we considered the possibility that they trigger im-
mune sensing in tumors. Therefore, we mapped TCGA RNA-
Seq data to a recently published annotation of 66 expressed
ERV family members (Table S5B, Data S4D) and assessed asso-
ciations with cytolytic activity (Mayer et al., 2011). By comparing
GTEx and TCGA tissue controls to TCGA tumor samples, we
observed numerous instances of ERVs demonstrating re-activa-
tion in tumors, including one instance of an ERVH-2 element52 Cell 160, 48–61, January 15, 2015 ª2015 Elsevier Inc.exceeding 2,700 reads per million in a stomach adenocarcinoma
(Data S4E). From these data we surprisingly discovered a con-
servative set of three tumor-specific endogenous retroviruses
(‘‘TSERVs’’) all with minimal to undetectable expression in
normal tissues and elevated expression in tumor tissues
(Figure 4A).
Assessing the gene expression correlates of each TSERV in
the tumor type exhibiting highest expression, we observed that
immune pathways were typically the most significantly enriched
(Table S5C). Many ERVs, in addition to the TSERVs, demon-
strated association with CYT in multiple tumor types (Figure 4B).
While we cannot determine whether ERVs activate immunity or
inflammation triggers ERVs (Manghera and Douville, 2013), we
conclude that ERVs are highly dysregulated in tumors and spec-
ulate that they may yield tumor-specific peptide epitopes (Boller
et al., 1997) or act as immunological adjuvants to activate local
immunity (Yu et al., 2012).
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Figure 4. Endogenous Retroviruses Tied to Local Immunity
(A) RNA-Seq-derived ERV expression in reads per million (RPM) across 18 TCGA tumor types and 27 non-tumor tissue types (from TCGA and GTEx) for
three elements found to be tumor-specific. The expression ranges (minimum value to maximum value) are highlighted in orange (for tumor tissues) or green (for
non-tumor tissues).
(B) Spearman-rank correlations between CYT and ERV expression. Gray squares indicate non-significant association (unadjusted p > 0.05) and blank squares
indicate no overexpression of the given ERV in the given tumor type (expression strictly below the normal tissue maximum). Asterisks (*) denote Bonferroni-
significant associations (adj. p < 0.05).
See also Data S4 and Table S5.
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Figure 5. Gene Mutations Associated with
High or Low Immune Cytolytic Activity
(A) Only genes showing pan-cancer significance
(adj. p < 0.1, red for positive, blue for negative and
gray for non-significant association) for non-silent
mutation association with CYT are shown in top
row. Additional rows, clustered by similarity, show
independent significant (unadj. p < 0.05) enrich-
ment upon sub-analysis. The black wedges
represent the share of samples exhibiting muta-
tion. Bar plot indicates unadjusted pan-cancer p
values formutational association with CYT, dashed
lines indicating thresholds yielding 1% and 10%
FDRs.
(B) Association between CASP8 mutational status
and FasL (FASLG) (left axis) and TRAIL (TNFSF10)
(right axis) gene expression (TPM) for tumor types
demonstrating at least five instances of non-
synonymous CASP8mutation. Light and dark bars
correspond to wild-type and (nonsynonymous)
mutant samples, respectively. Box plots as in
Figure 1. p values are calculated by Wilcoxon
rank-sum test.
See also Data S5 and Table S6.Another potential source of antigens and immunostimulatory
ligands is dying cells. Thus, we explored the potential role for
necrosis in driving CYT and immune infiltration in general.
Rates of necrosis were highest in glioblastoma (Data S4F)
and showed modest positive association (p < 0.05) with CYT
in glioblastoma, bladder, and ovarian cancer, but notably, as-
sociation with macrophage markers was consistently stronger
(Data S4G).
Mutations in Specific Driver Genes Were Enriched in
Tumors with Higher Cytolytic Activity
We hypothesized that high cytolytic activity could select for
tumors with somatic mutations that render them resistant to
immune attack. We therefore asked whether CYT is associ-
ated with mutations in 373 ‘‘driver’’ genes that are frequently54 Cell 160, 48–61, January 15, 2015 ª2015 Elsevier Inc.mutated in cancer based on analysis of
TCGA exome sequencing data (q < 0.1
by MutSigCV [Lawrence et al., 2013];
Table S6A). Using a regression-based
approach to look for pan-cancer associ-
ation of these mutated genes with CYT,
controlling for tumor type and back-
ground mutation rate, we found 35
genes (adj. p < 0.1; Figure 5A, Data
S5A, Table S6B). In contrast, synony-
mous somatic mutations were not asso-
ciated with CYT (adj. pmin = 0.09). Of
the top ten CYT-associated mutations,
eight were also associated with an inde-
pendent marker of CTLs (CD8A; 10%
FDR; Data S5B), demonstrating the
robustness of our CYT metric. Of the in-
dividual tumor types, uterine, stomach,
and colorectal had the most associa-
tions (15, 11, 6, respectively) while kidney clear cell and
ovarian, which showed markedly higher CYT compared to
normal tissue, had just one each, and lung adenocarcinoma
had none. Strikingly, somatic mutations, except TP53, were
all positively associated with CYT, consistent with a model
in which tumors develop resistance mutations under selection
pressure.
We note that while we predicted that cytolytic activity would
have the strongest impact on the mutation landscape, we also
identified genemutations strongly associated with other immune
cell types/functions (adj. p < 0.01; Data S5B), including STK11
and VHL with reduced macrophage signature, BRAF with
increased expression of costimulatory genes, and AXIN2,
SNX25 and others with the differential enrichment score of
CD8+ T compared to Treg.
Higher CYT Was Associated with Mutations in Genes
Involved in Antigen-Presentation, Extrinsic Apoptosis,
and Innate Immune Sensing
Several themes emerged when we considered the known func-
tions of the identified genes.
First, the most enriched gene,CASP8 (adj. p = 8.83 107), is a
critical player in the extrinsic apoptosis pathway and was en-
riched in head and neck cancer, colorectal cancer, lung squa-
mous cell carcinoma, and uterine cancer (where it showed a
maximal mutation frequency of 7.0%). The pattern of mutation
was diffuse and suggested loss of function (Data S5C), a poten-
tial mechanism by which a tumor cell could evade FasL- or
TRAIL-induced apoptosis. Between FasL (FASLG) and TRAIL
(TNFSF10), FasL is most correlated with CASP8 mutations and
thus more consistent with such a hypothesis (Figure 5B). A study
in mice indeed demonstrated that blockade of CASP8 results in
tumor escape from CTLs (Medema et al., 1999), and our result
indicates that this may be a common mechanism in human
tumors (that may evade CTLs or NK cells). Interestingly, four
additional genes with significant but less definitive statistical
enrichment also had well-established roles in regulating extrinsic
apoptosis. These include, CNKSR1 (Garimella et al., 2014),MET
(Fan et al., 2001; Garofalo et al., 2009),CSNK2A1 (Ravi and Bedi,
2002; Izeradjene et al., 2005; Llobet et al., 2008; Wang et al.,
2006), and PIK3CA (Saturno et al., 2013; Song et al., 2010).
PIK3CA mutations, which were often the well-known activat-
ing alterations E545K and H1047R (Samuels and Ericson,
2006), showed their strongest enrichment in stomach cancer,
demonstrating a 20% mutation rate and a strong positive asso-
ciation with EBV infection (p = 2.9 3 1010). As in the case of
CASP8, mutations in each of these genes were more closely
associated with FASL expression than TRAIL expression. We
conclude that loss of the extrinsic apoptosis pathwaymay repre-
sent a general mechanism for tumors to escape immune cyto-
lytic activity.
Second, the invariant chain of MHCClass I,B2M, was the next
most strongly enriched gene (adj. p = 7.13 103), showing inde-
pendently significant association in uterine, breast, colorectal
cancer, and stomach cancer, which exhibited the highest rate,
5.7%. The most frequent event was the same CT dinucleotide
deletion observed previously in melanoma patients relapsing
from T cell-based immunotherapy (Chang et al., 2005). The
MHC Class I locus itself was also significant (Table S6C; HLA-
A, -B, -C mutations considered jointly, adj. p = 5.3 3 102).
HLA-A and HLA-B alleles were mutated about three times as
frequently as HLA-C alleles. No specific alleles showed strong
evidence for being especially frequently mutated. The tumor
types with the highest rates of HLA mutation, stomach cancer
(14%), cervical cancer (12%), and head and neck cancer
(11%), were also among those with frequent viral involvement.
However, viral infection was not significantly associated with
HLA mutation in any of them (Table S6D). Given the requirement
of MHC Class I and B2M in presenting tumor antigens to cyto-
toxic CD8 T cells, we consider the enrichment of MHC Class I
and B2M mutations in high-CYT tumors (Khong and Restifo,
2002) as an independent and strong validation of CYT as a mea-
sure of cytolytic activity. While MHC Class II genes were not
significantly mutated pan-cancer, Class II gene mutations,considered collectively, were positively associatedwith CYT (un-
adj. p = 0.017) with independent significance in bladder cancer
(unadj. p = 0.0084).
Other hits included the CT antigens MORC4 (Liggins et al.,
2007) and SSX5 (Ayyoub et al., 2004) and genes with roles in
innate immune sensing, including DDX3X (Oshiumi et al., 2010)
and ARID2 (Yan et al., 2005). We also note that mutant TP53 is
negatively correlated with CYT, which may be explained either
by a role for p53 in regulating immunity (e.g., loss of p53-regu-
lated stress ligands that induce cytoxicity, [Textor et al., 2011])
or from absence of viral infection (consistent with p53 mutations
being anti-correlated with viral infection in stomach [p = 2.3 3
105] and head and neck cancer [p = 2.6 3 104]; Table S6D).
Because MSI-high colorectal tumors are known to be immu-
nogenic (Kloor et al., 2010), we also considered whether MSI-
high tumors were enriched for mutations in particular genes
with respect to MSI-low and microsatellite stable (MSS) tumors.
Mirroring the CYT analysis, CASP8 and MHC Class I mutations
were the most enriched mutations in MSI-high tumors (p adj. =
1.5 3 105 and 1.4 3 1012, respectively), with COL5A1,
SMC1A, CIC, ARID2, CNKSR1, and DNMT3A also significant
(adj. p < 0.05) (Table S6E).
Finally, we note that some candidate genes with well-known
immune function (Table S6A) did not show association with
CYT. However, enrichment in the expression of immune-related
genes were observed in tumors with mutations in some of these
genes (TNFRSF14, CLEC4E, CD1D, IL32; Table S6F).
Loci Containing Known Immune Regulators Show Copy
Number Alterations Associated with CYT
We also considered the possibility that specific regions of the
genomemay be preferentially focally amplified or deleted (based
on a data set of TCGA samples profiled with SNP6.0 arrays) in
high- or low- CYT tumors. As with the point mutation analysis,
we looked for pan-cancer CYT association with copy number
alterations (CNAs) using regression and controlling for cancer
subtype and background mutation rate (of amplifications and
deletions). This approach yielded 13 significantly amplified re-
gions (with three adjacent to each other on 6q) and one sig-
nificantly deleted region (FDR = 10%) (Figure 6A, Table S7).
Although CNAs include variable segments of a chromosomal re-
gion and do not typically identify causative genes, many of the
identified regions harbored plausible candidates.
On chromosomes 9 and 8, we found two well-known targets
of cancer immunotherapy. First, amplification of 9p23-p24.2
(Figure 6B), a region including PDL1 (CD274) and PDL2
(PDCD1LG2), was positively associated with CYT in lung squa-
mous cell carcinoma, head and neck cancer, cervical cancer,
stomach cancer, and colorectal cancer (Figure 6E). While tumor
cells and tumor infiltrating leukocytes are known to express
these ligands, our results suggest that tumor-expressed ligands
affect tumor fitness in the presence of cytolytic activity. Second,
a locus near 8p11.21-8p11.23 (Data S6A) showed increased
probability of amplification in low-CYT tumors (pan-cancer and
breast) and is adjacent to IDO1 and IDO2, enzymes that degrade
extracellular tryptophan and create a potent immunosuppres-
sive microenvironment, which may explain the associated
reduction in CYT (Uyttenhove et al., 2003).Cell 160, 48–61, January 15, 2015 ª2015 Elsevier Inc. 55
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Figure 6. Amplifications and Deletions Are Associated with Cytolytic Activity in Tumors
(A) The significance of association between CYT and amplification (orange) and between CYT and deletion (green) for all genic loci. Rightward lines show un-
adjusted p values for instances in which the lesion was positively associated with CYT, and leftward lines show unadjusted p values for instances in which the
lesion was negatively associated with CYT. Dotted lines represent the significance cutoffs yielding 1% and 10% FDRs (and also appear in parts B–E). Labels on
the right side mark events significant at the 10% FDR, plus B2M. Potential driver genes appear in parentheses.
(B) Locus zoom on the 9p24.2-p23 amplification, each bar corresponding to a single gene. Labeled genes include those with driver potential or those on the locus
boundary.
(C) Locus zoom on the region containing B2M, which was not genome-wide significant.
(D) Locus zoom on the 17p13.1 amplification.
(E) Significant associations between CNAs and CYT on the pan-cancer and cancer-specific level (as in Figure 5). Pan-cancer significance was defined at a 10%
FDR, and significance for individual tumor types was defined at unadjusted p < 0.05. Positive association is indicated with red circles, negative with blue circles,
and non-association with gray circles. Black wedges indicate the share of samples exhibiting the event (i.e., non-zero GISTIC score at the locus). Bar plot in-
dicates unadjusted pan-cancer p values for CNAs, sorted by significance, with dashed lines indicating thresholds yielding 1% and 10% FDRs.
See also Data S6 and Table S7.In addition, potential new targets were identified. These
included 17p13.1, which was preferentially amplified in low-
CYT tumors (Figure 6D), including breast and ovarian. The
peak genes, ALOX12B/ALOX15B (12/15-LO) regulate immunity
in many ways, including blocking the uptake of apoptotic cells
by inflammatory monocytes in a manner that decreases antigen
presentation to T cells (Uderhardt et al., 2012), which may56 Cell 160, 48–61, January 15, 2015 ª2015 Elsevier Inc.explain the observed decrease in CYT. Further supporting this
model, the amplification was associated with higher necrosis in
breast (p = 0.002) and kidney clear cell cancer (p = 0.0002),
though not ovarian cancer. Other peaks included ones near
TNFRSF1A and PRDM1 (Data S6A) as well as a suggestive,
but not genome-wide significant, enrichment atB2M (Figure 6C).
In considering how other enrichment signatures might associate
Virus
Neo-Ags
ERVs?
B2M, HLA
CASP8
PDL1,2 (  )
Induction of cytolytic activity:
immune-inducing factors
positively correlate with CYT
A
Emergence of evading subclones:
evasion lesions positively correlate
with CYT
B
p53
ALOX
IDO1,2
Emergence of suppressive subclones:
suppressive lesions negatively correlate
with CYT
C
Figure 7. Proposed Model for Evolution of
Tumor-Immune Associations
(A) As the tumor develops, we propose that
intrinsic tumor factors—such as mutated neo-
antigens or viruses—induce local immune in-
filtrates (blue circles) that include cytolytic effector
cells (expressing GZMA/PRF1; red circles) that kill
tumors (daggers). These factors are expected to
be positively correlated with CYT across tumors.
(B and C) Under pressure from cytolytic immune
cells, subclones with resistance mutations will
grow out over time. (B) One subset of these mu-
tations would enable tumors to evade killing, but
does not impact the infiltrate, and are positively
correlated with CYT (i.e., higher infiltrate samples
are enriched for these mutations). (C) Another
subset suppresses the immune infiltrate (i.e., lower
infiltrate samples are enriched for these muta-
tions), and is negatively correlated with CYT.
Notably, p53 mutations and ALOX amplifications
were also significantly negatively associated with
CD8A, suggesting a reduction in cell numbers and
not just activity.
See also Data S7 and Table S8.with CNAs (Data S6B), we observed a dramatic positive associ-
ation between increased MHC Class I expression and amplifica-
tion of the MHC Class II complex (adj. p < 5 3 104).
DISCUSSION
Based on the notion that effective natural anti-tumor immunity
requires a cytolytic immune response, we quantified cytolytic ac-
tivity using a simple expression metric of effector molecules that
mediate cytolysis. Our analysis was designed to address which
genetic and environmental factors drive tumor-associated cyto-
lytic activity, and how this cytolytic activity selects for genetic
resistance in tumors. Our results suggest that neoantigens and
viruses are likely to drive cytolytic activity, and reveal known
and novel mutations that enable tumors to resist immune attack.
We considered several explanations for the elevated immune
cytolytic activity observed in some tumors (Figure 7A). First,
we asked whether neoantigens play a role. These are a compel-
ling set of antigens because of their absence from the thymus
and thus lack of central tolerance that would normally delete
cognate high-affinity T cells. Indeed, we found that neoantigen
load positively associated with cytolytic activity across multiple
tumor types, and that neoantigens appear to be depleted in
tumors relative to their expected numbers based on the silent
mutation rate, consistent with the notion of immunoediting
(Schreiber et al., 2011). Second, when we analyzed CT antigens
that are expressed selectively in tumors, we could not detect a
positive correlation between the number of expressed CT genes
and cytolytic activity. In addition, CT antigen genes were not
contained within deletions associated with CYT, contrary to
what would be expected if there were immune pressure on CT
antigens. Although we did not uncover a role for CT antigens in
spontaneous immunity (perhaps because our methods werenot optimized to detect CT depletion), we did highlight a subset
of 60 CT antigens that are highly tumor-specific and may be (or
are already) excellent targets for immunotherapy, including vac-
cines, adoptive T cell transfer, or CAR-T therapy. Third, we asked
whether viruses could be inducers of immune responses. In
some tumors, we observed that cytolytic activity does indeed
associate with the presence of exogenous or endogenous vi-
ruses, and we expect that some viruses would trigger immunity
through RNA and DNA sensors and generate immunogenic anti-
gens for the adaptive immune response.
To learn more about how tumors adapt to attack by cytolytic
immune cells, we also searched for enrichment of somatic ge-
netic alterations in tumors with high versus low cytolytic activity.
As expected, we observed enrichment of mutations in antigen
presentation machinery (thus validating our cytolytic metric),
including HLA and B2M, as well as extrinsic apoptosis genes,
such as CASP8, that would prevent cytolytic cells from killing tu-
mors via FasL-Fas interactions. In addition, we found cytolytic
activity correlating with amplifications in regions containing
genes that function in immunosuppression, such as PDL1/2.
Most of the identified mutations—including HLA, B2M, and
CASP8—were positively correlated with CYT and are likely to
represent autonomous escape mechanisms (Figure 7B). In addi-
tion, we identified a smaller number of mutations that correlated
negatively with cytolytic activity—including IDO1 and IDO2, p53,
and the ALOX locus—and may represent non-autonomous
mechanisms of suppressing immunity (Figure 7C). Finally, we
were surprised that CYT-associated genetic lesions represent
10% of drivers, and these genes had largely not been studied
in the context of immunity. However, given the importance of
immune responses in controlling tumor progression (Page`s
et al., 2005), tumors may have evolved several mechanisms
of evasion.Cell 160, 48–61, January 15, 2015 ª2015 Elsevier Inc. 57
Our approach has allowed us to positively identify the subset
of tumor types that are sensitive to spontaneous cytolytic activity
(Data S7, Table S8). If we consider positive correlation of HLA,
B2M, orCASP8mutations with CYT as a ‘‘signature’’ of selection
pressure by the immune system, we find that colorectal, uterine,
stomach, head and neck, cervical, lung squamous, and breast
tumors are most susceptible to immune elimination. If we further
consider depletion of neoepitopes as an independent signature
of selection, we identify colorectal as well as kidney clear cell
cancer as immune-susceptible tumors. For these tumor types,
we thus suggest that spontaneous tumor immunity can delete tu-
mor cells.
For several tumor types, we did not find evidence for immu-
noediting. This could be due to: insufficient power to detect
associations in tumors with low rates of spontaneous immunity,
non-genetic evasion mechanisms that we cannot detect, or true
absence of immune cytolytic activity (perhaps for thyroid and
prostate cancers, for example).
Finally, the mutations associated with cytolytic activity reveal
potential genetic biomarkers for predicting outcome and candi-
date targets for immunotherapy. To assess the utility of these
markers, one would need to genotype tumors for the 35 identi-
fied genes at clonal or subclonal levels, and test if pre-treatment
or post-treatment mutations predict refractoriness or relapse in
response to cytolytic immunotherapy. We predict that the pres-
ence of these mutations (assuming they do not lead to complete
loss of susceptibility) indicates that re-activation of CD8 T cells
would be therapeutically effective. In addition, we identified
new candidates for therapeutic development, including the
ALOX enzymes and their products, the PIK3CAprotein that is en-
riched in activating mutations in high-CYT stomach cancers, and
FASL whichmay be useful to upregulate in T cells to enhance the
anti-tumor activity of adoptively transferred T cells.
Analysis of TCGA samples has revealed environmental and
genetic mechanisms that impact tumor-immune interactions.
While we chose to focus on cytolytic activity because of its cen-
tral role in tumor elimination and the feasibility of monitoring its
activity, we did not consider other tumoricidal activities (such
as antibody-dependent cell-mediated cytotoxicity) because we
are not aware of transcript-based markers for these activities.
In addition, the CYT metric we used is transcript-based and
thus may not reflect changes in cytolytic activity due to post-
transcriptional regulation, and is a snapshot in time that may
miss previous activity that impacted tumor growth. We antici-
pate that improved experimental measurements of anti-tumor
immune activity will further reveal the genetic and epigenetic
changes that underlie co-evolution of tumor cells and immune
cells.EXPERIMENTAL PROCEDURES
Tumor and Normal Samples and Data Sets
Analyzed samples represent untreated primary tumors, except for melanoma,
which included metastases. Metastases to lymph nodes were always
excluded as were patients that received neo-adjuvant therapy. Gene-level
RNA-Seq expression data were accessed from GDAC Firehose (http://gdac.
broadinstitute.org) (tumors and normals) and from the GTEx web portal
(http://www.gtexportal.org) (normals only). RNA-Seq-based sequence data
from the corresponding projects were accessed through CGHub and the58 Cell 160, 48–61, January 15, 2015 ª2015 Elsevier Inc.Short Read Archive (SRP012682), respectively, and used to estimate expres-
sion of endogenous and exogenous viruses. Additional gene expression data
were accessed from the CCLE web portal (http://www.broadinstitute.org/
ccle/home; Barretina et al., 2012) (Affymetrix U133+2 microarrays), Fantom5
(FANTOM Consortium et al., 2014) (cap analysis gene expression), and
DMAP (Novershtern et al., 2011) and used to evaluate gene expression
markers. Whole exome sequencing-derived point mutation calls were ac-
cessed from TumorPortal (Lawrence et al., 2014), Synapse workspace
syn1729383 (https://www.synapse.org/#!Synapse:syn1729383; Kandoth
et al., 2013), TCGA Data Portal (https://tcga-data.nci.nih.gov/tcga), GDAC
Firehose (http://gdac.broadinstitute.org/), and the TCGA Research Network
stomach adenocarcinoma publication (Cancer Genome Atlas Research
Network, 2014). Whole exome sequencing-based sequence data, used to
call HLA genotypes and mutations, were accessed through CGHub. GISTIC2
(Mermel et al., 2011) gene-level, zero-centered, focal copy number calls for
each patient were accessed from GDAC Firehose. Clinical data for each tumor
type were accessed from the TCGA public access web portal. Tables S1 and
S2 catalog the TCGA and GTEx samples included in the study.
Cytolytic Activity and Other Cell Type-Specific Signatures
Cytolytic activity (CYT) was calculated as the geometric mean of GZMA and
PRF1 (as expressed in TPM, 0.01 offset). Marker genes for specific cell types
were identified as those with expression at least 2-fold greater than observed
in any other cell type (using Fantom5 and DMAP), and enrichment was calcu-
lated using ssGSEA (Barbie et al., 2009). CYT-dependent survival analyses
via Cox proportional hazards were performed by separating patients into a
high-CYT cohort and a low-CYT cohort, each with an identical admixture of
histology-stage combinations.
Expression of Exogenous and Endogenous Retroviruses
Viral expression was quantified by mapping unmapped RNA-Seq reads (bow-
tie2 [Langmead and Salzberg, 2012]) to viral sequence variants deposited in
GenBank and normalizing against the count of mapped reads. Positive identi-
fication required at least 300 nt of unique sequence to map to the viral genome
and expression exceeding that observed in GTEx normals. To quantify the
expression of endogenous retroviruses, RNA-Seq data (from TCGA and
GTEx) was re-mapped (bowtie2 [Langmead and Salzberg, 2012]) to an anno-
tation of known expressed elements (Mayer et al., 2011). For each ERV, the
95th percentile expression value was calculated per tissue type, and if this
value was less than <10 TPM in all normal tissues, >10 TPM in a tumor type,
and at least 5-fold higher than in all non-tumor tissues, then the ERV was
deemed tumor-specific.
Tumor-Specific HLA Typing, HLA-Binding Neoepitope Prediction
and CT Antigen Identification
The 4-digit HLA type for each sample was inferred using POLYSOLVER
(POLYmorphic loci reSOLVER), which uses a normal tissue .bam file as input
and employs a Bayesian classifier to determine genotype (unpublished, S.A.S.,
C.J.W., and G.G.). By comparing to matched tumor .bams, POLYSOLVER
also identified HLA mutations. Neo-epitopes were predicted for each patient
by defining all novel amino acid 9mers and 10mers resulting from mutation in
expressed genes (median >10 TPM in the tumor type) and determining whether
the predicted binding affinity to the patient’s germline HLA alleles was < 500 nM
using NetMHCpan (v2.4) (Nielsen et al., 2007; Rajasagi et al., 2014). A set of
potential cancer testis (CT) antigens was defined by finding known CT antigens
(Almeida et al., 2009) with negligible expression in GTEx normal tissues (95th
percentile value < 1 TPM in all somatic tissue types).
Comparison of Expected to Observed Neoantigen Load per Tumor
To test whether the count of neo-epitopes was different from expected
(ignoring the expression-based filter and excluding indels), the rate at which
each mutational spectrum produces neo-epitopes was calculated empirically
pan-cancer, and the silent mutations in each patient used to infer the expected
ratio of neo-epitopes per non-silent mutation. This was compared to the actual
ratio observed in the patient. Random shuffling of HLA genotypes among pa-
tients served as a control.
Association of CYT with Point Mutations and Amplifications/
Deletions
Candidate genes were tested for non-silent point mutation association with
CYT using a regression-based approach with CYT (rank-transformed) as the
dependent variable, mutational status of the gene in question as the indepen-
dent variable, and cancer histological subtype and the background rate of
non-silent point mutations as additional control variables. Hits were defined
at adj. p < 0.1. Candidate genes were defined by running MutSigCV (Lawrence
et al., 2013) on each tumor type separately and all the tumor types collectively
(adj. p < 0.1) and merging with a previously published result set (Lawrence
et al., 2014). To assess for association between CYT and copy number alter-
ations, a regression-based approach was likewise used, using CYT (rank-
transformed) as the dependent variable, amplification, or deletion signal as
the independent variable, and cancer histological subtype and the background
rate of copy number alteration as additional control variables. ‘‘Peaks’’ were
defined as contiguous regions with p < 0.01, and permutation testing was
used to determine whether the peak score (based on the most enriched
gene in the region) was truly significant (adj. p < 0.1).SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, one
figure, eight tables, and seven data sets and can be found with this article on-
line at http://dx.doi.org/10.1016/j.cell.2014.12.033.
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